Massachusetts Science News (United States)

Cambridge Healthtech Institute & Bio-IT World organizes a dinner short course on June 6, 2012 at the Royal Sonesta Hotel Boston in Cambridge, MA. The course will be held at the conclusion of day one of the Structure-Based Drug Design conference.

Delegates now have the option to choose from 3 moderated breakout discussion groups in the exhibit hall at this conference that is set for February 21-23, Moscone North Convention Center, San Francisco, CA (part of CHI's Molecular Med TRI-CON 2012).

Hear breakthroughs in the field of pathology such as predictive cancer biomarkers, decoding cancer molecular profiles, next generation sequencing, circulating tumor cells, etc. View final agenda at www.healthtech.com/tdx.

Event Focus will be Predicting Biological and Kinetic Profiles from Structure

Delegates now have the option to choose from 3 moderated breakout discussion groups in the exhibit hall at this conference that is set for February 21-23, Moscone North Convention Center, San Francisco, CA (part of CHI's Molecular Med TRI-CON 2012).

Agenda Announcement and Registration Reminder for CHI’s Eighth Annual PEGS the essential protein engineering summit, April 30 – May 4, Boston, MA

100+ pharma and biotech companies from around the world will participate at CHI's 4th annual Integrated R&D Informatics & Knowledge Management conference to be held in San Francisco, CA on February 21-23, 2012.

Badri Rengarajan, M.D., Medical Director, will present in the modeling and simulation tools to improve Phase III success session.

The U.S. merchant hydrogen market rose from $3.36 billion in 2010 to $3.44 billion in 2011. By 2016, the market should reach $3.87 billion, yielding a compound annual growth rate (CAGR) of 2.4% for the period.

Dr. Quackenbush will present in the translating biomarker driven cancer treatments into practice session.

Delegates now have the option to choose from 3 moderated breakout discussion groups at this conference that is set for February 21-23, San Francisco, CA (part of CHI's Molecular Med TRI-CON 2012).

Dr. Leach will participate in a keynote session at this conference scheduled for Feb. 21-23, 2012, San Francisco, CA. The conference is organized by Cambridge Healthtech Institute.

This Insight Pharma Report focuses on the applications, technology and market aspects of high-content analysis.

Dr. Craig Jordan announces presentation at upcoming symposium on February 19-20, 2012 in San Francisco, CA.

CHI’s Cancer Biologics conference is being held at the Molecular Med TRI-CON 2012 on February 21-23 at the Moscone in San Francisco.

This conference is part of the Molecular Med TRI-CON 2012 event on February 21-23, 2012 at the Moscone North Convention Center in San Francisco, CA. Advance registration discounts ends on January 13.

Dr. Williams will present on evidentiary standards for surrogate endpoints, genetic testing & CDx.

CHI’s Bioinformatics & Cancerinformatics conference is a new program being held at the Molecular Med TRI-CON 2012 on Feb. 21-23 at the Moscone in San Francisco. This conference is part of the many program options available at the Tri-Conference.

Amarin’s CMO to lead line-up of thought leaders at Cambridge Healthtech Institute’s executive and scientific forum.

Webinar shows attendees how to design for the least number of heat sinks and potentially none at all; Thursday, December 15, 2PM EST

Cambridge Healthtech Institute & Bio-IT World organizes a two hour dinner short course on June 7, 2012, Royal Sonesta Hotel Boston, Cambridge, MA. The course will be held at the conclusion of day two of the Structure-Based Drug Design conference.

This course will be held on June 4, 2012, Loews Hotel, Philadelphia, PA. The course will be held prior to the start of CHI’s Innovative Tissue-Based Diagnostics conference.

Cambridge Healthtech Institute & Bio-IT World organizes a dinner short course on June 6, 2012 at the Royal Sonesta Hotel Boston in Cambridge, MA. The course will be held at the conclusion of day one of the Structure-Based Drug Design conference.

Join us for a roundtable discussion during the Cancer Biologics Conference at the Tri-Conference. Discussion moderated by: Norman J. Maitland, Ph.D., Chief Scientific Officer, Procure Therapeutics Ltd.

Join 150+ delegates involved in IT and informatics at pharma, biotech & academic institutions at CHI’s Molecular Med TRI-CON 2012 event on Feb. 21-23, 2012 at the Moscone North Convention Center in San Francisco, CA. www.TriConference.com/IRD.

Delegates now have the option to choose from 3 moderated breakout discussion groups in the exhibit hall at this conference that is set for February 21-23, Moscone North Convention Center, San Francisco, CA (part of CHI's Molecular Med TRI-CON 2012).

Hear breakthroughs in the field of pathology such as predictive cancer biomarkers, decoding cancer molecular profiles, next generation sequencing, circulating tumor cells, etc. View final agenda at www.healthtech.com/tdx.

Event Focus will be Predicting Biological and Kinetic Profiles from Structure

Delegates now have the option to choose from 3 moderated breakout discussion groups in the exhibit hall at this conference that is set for February 21-23, Moscone North Convention Center, San Francisco, CA (part of CHI's Molecular Med TRI-CON 2012).

Agenda Announcement and Registration Reminder for CHI’s Eighth Annual PEGS the essential protein engineering summit, April 30 – May 4, Boston, MA

Cambridge Healthtech Institute’s Third Annual Anti-Inflammatories: Small Molecule Approaches will be held April 17-18, 2012 in San Diego as part of the Drug Discovery Chemistry conference. Early registration discount expires January 27th.

100+ pharma and biotech companies from around the world will participate at CHI's 4th annual Integrated R&D Informatics & Knowledge Management conference to be held in San Francisco, CA on February 21-23, 2012.

Badri Rengarajan, M.D., Medical Director, will present in the modeling and simulation tools to improve Phase III success session.

The U.S. merchant hydrogen market rose from $3.36 billion in 2010 to $3.44 billion in 2011. By 2016, the market should reach $3.87 billion, yielding a compound annual growth rate (CAGR) of 2.4% for the period.

Dr. Quackenbush will present in the translating biomarker driven cancer treatments into practice session.

Delegates now have the option to choose from 3 moderated breakout discussion groups at this conference that is set for February 21-23, San Francisco, CA (part of CHI's Molecular Med TRI-CON 2012).

Dr. Leach will participate in a keynote session at this conference scheduled for Feb. 21-23, 2012, San Francisco, CA. The conference is organized by Cambridge Healthtech Institute.

Chris Porter, Product Manager, HPC Cloud, will lead a luncheon presentation at CHI’s Cloud Computing: Applications and Advances in Life Sciences R&D Symposium next month in San Francisco, CA.

This Insight Pharma Report focuses on the applications, technology and market aspects of high-content analysis.

Your Asian Glow is a condition in which an individual's face and/or body experiences flushes or blotches as a result of an accumulation of Acetaldehyde, a metabolic byproduct of the catabolic metabolism of alcohol. How to cure Asian Glow...

Janis Research Company is pleased to announce the model JDry-500-TLSV top-loading cryogen-free dilution refrigerator (DR) system with sample in vacuum. The sample base temperature is 20mK-40mK depending on wires and cables installed on sample mount.

Janis Research Company is pleased to announce that it is offering a new series of micro-manipulated probe systems with a rotatable magnetic field. The typical vibration level is +/- 25 nm and the long-term drift is approximately 2 nm/min.

Event Focusing on Novel Small Molecules as Therapeutic Targets

Dr. Craig Jordan announces presentation at upcoming symposium on February 19-20, 2012 in San Francisco, CA.

Cambridge Healthtech Institute to Hold Inaugurual Next-Generation Pathology Symposia at 19th International Molecular Med Tri-CON 2012.

CHI’s Cancer Biologics conference is being held at the Molecular Med TRI-CON 2012 on February 21-23 at the Moscone in San Francisco.

This conference is part of the Molecular Med TRI-CON 2012 event on February 21-23, 2012 at the Moscone North Convention Center in San Francisco, CA. Advance registration discounts ends on January 13.

Dr. Williams will present on evidentiary standards for surrogate endpoints, genetic testing & CDx.

CHI’s Bioinformatics & Cancerinformatics conference is a new program being held at the Molecular Med TRI-CON 2012 on Feb. 21-23 at the Moscone in San Francisco. This conference is part of the many program options available at the Tri-Conference.

Amarin’s CMO to lead line-up of thought leaders at Cambridge Healthtech Institute’s executive and scientific forum.

Webinar shows attendees how to design for the least number of heat sinks and potentially none at all; Thursday, December 15, 2PM EST

CHI confirms new speakers for its keynote session on cancer clinical trials in the era of personalized medicine lead by Roche Holding AG, UCSF Helen Diller Family Comprehensive Cancer Center, and Samuel Oschin Comprehensive Cancer Institute.

Cambridge Healthtech Institute just adds an interactive panel discussion to take place at its Integrated R&D Informatics & Knowledge Management conference on Feb. 21-23, 2012, San Francisco, CA.

Draper Laboratory officials discussed professional development in the engineering field, as well as ways to use technology to assist local communities, during a National Society of Black Engineers (NSBE) northeastern regional conference last month.

An entirely new expanded offering means no settling – get the right meter solution that fits your needs

Cambridge Healthtech Institute’s (CHI) BioPharma Strategy Series is proud to present the first conference on Phase III Clinical Trials: Strategic Decisions for Successful Drugs to be held in Philadelphia, PA on March 12-13, 2012.

Discussions led by industry experts, such as Malcolm Young (e-Therapeutics), Jeremy Jenkins (Novartis), and John Burke (Boehringer Ingleheim) will address the implementation of de-risking approaches into the corporate organization.

CHI’s Oncology Clinical Trials conference will highlight three Xalkori case studies by Pfizers’ Hakan Sakul, Ph.D., Keith Wilner, Ph.D., and Erling Thor Donnelly, Ph.D., R.A.C. This conference is part of the Molecular Medicine Tri-Conference.

Navigating the Future of Genomic Technologies. March 5-8, 2012 at the Hilton San Diego Resort

When: November 17-18, 2011 Where: Omni Parker House - Boston, MA

CHI’s Oncology Clinical Trials conference will highlight two case studies by Seattle Genetics’ Eric Sievers, M.D., Vice President, Clinical Affairs, and Elaine S. Waller, Pharm.D., M.B.A., Senior Vice President, Regulatory Affairs.

CHI’s Oncology Clinical Trials conference will highlight three Zelboraf case studies by Genentech, F. Hoffmann-La Roche, and Roche Molecular Systems. This conference is part of the many program options available at the Tri-Conference.

CHI’s Integrated R&D Informatics conference will once again be held at the Molecular Med TRI-CON 2012 on Feb. 21-23, 2012 at the Moscone in San Francisco, CA. This conference is part of the many program options available at the Tri-Conference.

Cambridge Healthtech Institute Announces 11th Annual PepTalk: The Protein Science Week, January 9 – 13, 2012 in San Diego, CA

Hear strategies addressing the role of miRNA in human development and disease, and to explore the impact of this new research for drug and diagnostic development.

CHI’s Oncology Clinical Trials: Bringing Targeted & Tailored Cancer Therapy will take place on Feb. 21-23, 2012 at the Moscone in San Francisco, CA. This conference is part of the many program options available at the Molecular Med TRI-CON 2012.

New Trends in Preventive and Therapeutic Vaccines: R&D Activities and Commercial Prospects

A 2-day Symposium on "Cloud Computing: Applications and Advances in Life Sciences R&D" will take place on Feb. 19-20, 2012 at the InterContinental Hotel, San Francisco. This symposium is part of many offerings at the Molecular Med TRI-CON 2012.

Stripercoast Surfcasters Club Urges Public Comment On Menhaden Addendum V, in favor of reducing the coastwide harvest and putting an end to the chronic overfishing of this important forage fish.

Artemis Capital Partners closed a minority growth equity investment in Janis Research Company, LLC.